Purpose Of Review: Etanercept was the first tumour necrosis factor inhibitor approved to treat rheumatoid arthritis (RA) in the United States (US) and Europe. The recent patent expiration of the etanercept originator ENBREL in Europe has facilitated the development of biosimilar products, creating the prospect of reduced treatment costs. In this article, we review the original trials for etanercept in RA to facilitate critical appraisal of biosimilar trial data.
Recent Findings: Two etanercept biosimilars are currently approved in Europe and/or the US, SB4 (Benepali) and GP2015 (Erelzi), having met the pre-specified equivalence criteria for biosimilarity. Trial data demonstrates subtle differences in clinical outcomes and adverse events between the biosimilars and the reference product (RP). The development of etanercept biosimilars may reduce the financial burden of treating RA, but real-world data regarding efficacy and safety in comparison to the RP will be vital to assess for meaningful differences.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244902 | PMC |
| http://dx.doi.org/10.1007/s11926-018-0799-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Implementation of an Early Referral Programme for Patients With Hand Arthralgia.
J Eval Clin Pract
February 2025
Instituto Mexicano del Seguro Social, IMSS Hospital General de Zona Número 17, Monterrey, Nuevo León, México.
Introduction: Rheumatoid arthritis (RA) is a progressive autoimmune inflammatory disease. According to the European League Against Rheumatism (EULAR), the stages of RA progression include pre-RA, preclinical RA, inflammatory arthralgia, arthralgia with positive antibodies, arthralgia suspected of progressing to RA, undifferentiated arthritis and finally established RA. According to the Community Oriented Program for Control of Rheumatic Diseases (COPCORD), the prevalence of RA in Mexico is 1.
View Article and Find Full Text PDFCOVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time.
Rheumatol Int
December 2024
Department of General Practice N2, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.
We discuss the paper recently published in Rheumatology Internationa. This article reflects on the prevalence of autoimmune rheumatic diseases (ARD) during the COVID-19 pandemic (2020-2023) and compares the same with the pre-pandemic period (2016-2019). We assume that SARS-CoV-2 triggers ARD.
View Article and Find Full Text PDFWater-based interventions in rheumatic diseases: mechanisms, benefits, and clinical applications.
Rheumatol Int
December 2024
Chair of Psychiatry and Narcology, Astana Medical University, Astana, Kazakhstan.
Chronic pain and restricted mobility, hallmark features of rheumatic diseases, substantially affect patients' quality of life, often resulting in physical disability and emotional distress. Given the long-term nature of these conditions, there is a growing interest in complementary therapeutic approaches, emphasizing the need to explore non-pharmacological treatments. Hydrotherapy, balneotherapy, and mud therapy have emerged as effective interventions to alleviate pain, reduce inflammation, improve joint mobility, and enhance overall physical and mental well-being.
View Article and Find Full Text PDFThe role of C-reactive protein and ferritin in the diagnosis of HLH, adult-onset still's disease, and COVID-19 cytokine storm.
Sci Rep
December 2024
International Collaboration On Repair Discoveries, School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada.
Cytokine storm syndromes such as hemophagocytic lymphohistiocytosis (HLH), Adult-onset Still's disease (AOSD), and COVID-19 cytokine storm (CCS) are characterized by markedly elevated inflammatory cytokines. However clinical measurement of serum cytokines is not widely available. This study examined the clinical utility of C-reactive protein (CRP) and ferritin, two inexpensive and widely available inflammatory markers, for distinguishing HLH from AOSD and CCS.
View Article and Find Full Text PDFA large-scale multi-omics polygenic risk score analysis identified candidate risk locus associated with rheumatoid arthritis.
Joint Bone Spine
December 2024
Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, School of Public Health, Health Science Center, Xi'an Jiaotong University, No. 76 Yan Ta West Road, 710061 Xi'an, China. Electronic address:
Objective: This study aimed to investigate the associations of multi-omics polygenic risk score (PRS) and rheumatoid arthritis (RA) to identify potential genes/proteins and biological pathways.
Methods: Based on multi-omics data from 48,813 participants in the INTERVAL cohort, we calculated multi-omics PRS for 13,646 mRNAs (RNASeq), 308 proteins (Olink), 2,380 proteins (SomaScan), 726 metabolites (Metabolon), and 141 metabolites (Nightingale). Using the generalized linear model, we first evaluated the associations between multi-omics PRS and RA in 58,813 UK Biobank participants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!